C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 5/08 (2006.01) A61K 35/18 (2006.01) A61K 38/20 (2006.01) C07K 14/55 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2133831
The properties of two recombinant human IL-2 analogues with mutations at Arginine 38 (.fwdarw. Alanine) and Phenylalanine 42 (.fwdarw. Lysine) were analyzed and compared to those of native IL-2. These analogues were found to maintain their ability to bind to the intermediate IL-2 receptor, p75, while binding only minimally to the high affinity p55 + p75 receptor complex. The analogues also maintained the ability to stimulate peripheral blood mononuclear cells to generate lymphokine activated killing (LAK). However, IL-1.beta. and TNF-.alpha. secretions were significantly reduced in response to the analogues, as compared to the native IL-2 molecule. These analogues are therefore potentially valuable low-toxicity alternatives to IL-2 in human immunotherapy and adoptive immunotherapy treatment strategies.
Grimm Elizabeth A.
Heaton Keith
Bereskin & Parr
Board Of Regents The University Of Texas System
LandOfFree
Low toxicity interleukin-2 analogues for use in immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low toxicity interleukin-2 analogues for use in immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low toxicity interleukin-2 analogues for use in immunotherapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1552475